Literature DB >> 26658716

Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.

Hiroaki Nomori1, Yue Cong2, Hiroshi Sugimura2, Yoshiaki Kato3.   

Abstract

PURPOSES: One of the limitations of fluorodeoxyglucose-positron emission tomography (PET) for N-staging in non-small cell lung cancer (NSCLC) is false-positive results due to lymphadenitis. This study was performed to examine whether DWI can correctly identify false-positive nodes on PET in NSCLC.
METHODS: Both PET and DWI were performed in 157 patients before surgery, which involved dissection of 1033 nodal stations. Of the 157 patients, 26 patients had pathological N1 or N2 disease. Each nodal station was classified as positive or negative on PET and DWI according to the cutoff value determined by the receiver operating characteristic curve. Short-axis diameters of lymph nodes were measured on computed tomography.
RESULTS: While hilar nodes did not show significant differences in the number of false-positives between PET and DWI, DWI showed fewer false-positives than PET in the mediastinum (p = 0.011). Of the 43 false-positive mediastinal nodes on PET, 35 (81 %) were negative on DWI. The mean size of the 43 false-positive nodes on PET was 9 ± 1 mm, which was significantly larger than mean size of 7 ± 3 mm of the 24 false-positive nodes on DWI (p = 0.002).
CONCLUSIONS: DWI can correctly identify false-positive nodes on PET in the mediastinum. The larger size of false-positive nodes on PET could be due to enlargement by lymphadenitis.

Entities:  

Keywords:  18F-Fluorodeoxyglucose; Diffusion-weighted imaging; Lung cancer; Lymph node; Positron emission tomography

Mesh:

Year:  2015        PMID: 26658716     DOI: 10.1007/s00595-015-1285-1

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  24 in total

1.  Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.

Authors:  Stefan A Reinsberg; Geoffrey S Payne; Sophie F Riches; Sue Ashley; Jonathan M Brewster; Veronica A Morgan; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2007-01       Impact factor: 3.959

2.  N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.

Authors:  Yoshiharu Ohno; Hisanobu Koyama; Takeshi Yoshikawa; Mizuho Nishio; Nobukazu Aoyama; Yumiko Onishi; Daisuke Takenaka; Sumiaki Matsumoto; Yoshimasa Maniwa; Wataru Nishio; Yoshihiro Nishimura; Tomoo Itoh; Kazuro Sugimura
Journal:  Radiology       Date:  2011-09-16       Impact factor: 11.105

3.  Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer.

Authors:  Koichi Fukumoto; Tetsuo Taniguchi; Noriyasu Usami; Koji Kawaguchi; Takayuki Fukui; Futoshi Ishiguro; Shota Nakamura; Kohei Yokoi
Journal:  Surg Today       Date:  2014-05-01       Impact factor: 2.549

4.  Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging.

Authors:  J Wang; S Takashima; F Takayama; S Kawakami; A Saito; T Matsushita; M Momose; T Ishiyama
Journal:  Radiology       Date:  2001-09       Impact factor: 11.105

5.  Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.

Authors:  Ryuji Murakami; Takeshi Sugahara; Hideo Nakamura; Toshinori Hirai; Mika Kitajima; Yoshiko Hayashida; Yuji Baba; Natsuo Oya; Jun-Ichi Kuratsu; Yasuyuki Yamashita
Journal:  Radiology       Date:  2007-03-13       Impact factor: 11.105

6.  Pleural lavage cytology predicts recurrence and survival, even in early non-small cell lung cancer.

Authors:  Federico Mazza; Enrico Ferrari; Paola Maineri; Beatrice Dozin; Giovanni Battista Ratto
Journal:  Surg Today       Date:  2014-05-10       Impact factor: 2.549

7.  The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer.

Authors:  Hubert Vesselle; Jeffrey M Pugsley; Eric Vallières; Douglas E Wood
Journal:  J Thorac Cardiovasc Surg       Date:  2002-09       Impact factor: 5.209

8.  Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?

Authors:  Yasuomi Ohba; Hiroaki Nomori; Takeshi Mori; Koei Ikeda; Hidekatsu Shibata; Hironori Kobayashi; Shinya Shiraishi; Kazuhiro Katahira
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03-29       Impact factor: 5.209

9.  Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.

Authors:  Yoshiharu Ohno; Hisanobu Koyama; Yumiko Onishi; Daisuke Takenaka; Munenobu Nogami; Takeshi Yoshikawa; Sumiaki Matsumoto; Yoshikazu Kotani; Kazuro Sugimura
Journal:  Radiology       Date:  2008-06-06       Impact factor: 11.105

10.  Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.

Authors:  Hiroaki Nomori; Takeshi Mori; Koei Ikeda; Koichi Kawanaka; Shinya Shiraishi; Kazuhiro Katahira; Yasuyuki Yamashita
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

View more
  2 in total

1.  Comparison of Conventional DWI, Intravoxel Incoherent Motion Imaging, and Diffusion Kurtosis Imaging in Differentiating Lung Lesions.

Authors:  Yu Zheng; Jie Li; Kang Chen; Xiaochun Zhang; Huan Sun; Shujiao Li; Xie Zhang; Zhenping Deng; Na Liang; Shihong Li
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

Review 2.  State-of-the-art MR Imaging for Thoracic Diseases.

Authors:  Yumi Tanaka; Yoshiharu Ohno; Satomu Hanamatsu; Yuki Obama; Takahiro Ueda; Hirotaka Ikeda; Akiyoshi Iwase; Takashi Fukuba; Hidekazu Hattori; Kazuhiro Murayama; Takeshi Yoshikawa; Daisuke Takenaka; Hisanobu Koyama; Hiroshi Toyama
Journal:  Magn Reson Med Sci       Date:  2021-04-29       Impact factor: 2.760

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.